medspa retatrutide Weight Loss Peptide Therapy Guide Flyer, Cheat Sheet Template, Insulin Injection Therapy Flyer, Med Spa Flyer, Instant Download Retatrutide, an investigational triple hormone

Patients receiving the highest dose of Retatrutide lost an average of 70 pounds over 80 weeks, compared with just 2.2% weight loss in the placebo group

Pancreatitis , significant gallbladder disease , or severe GI disease (e.g., gastroparesis)

The guide on how long to stay on semaglutide for weight loss covers the evidence and considerations for long-term versus defined-duration treatment

From a safety standpoint, retatrutide's known adverse effect profile from phase II trials includes: Nausea, vomiting, and diarrhoea (gastrointestinal effects common to GLP-1 receptor agonists) Reduced appetite and potential nutritional deficiencies with prolonged use Elevated heart rate observed in some trial participants Pancreatitis and gallbladder disease , which are recognised class cautions for GLP-1based therapies and should be considered in the context of retatrutide, although retatrutide-specific data remain limited Thyroid C-cell changes , observed in rodent studies with GLP-1 receptor agonists